Information Provided By: 
Fly News Breaks for January 20, 2016
GHDX
Jan 20, 2016 | 07:37 EDT
Leerink analyst Dan Leonard elevated Genomic Health to his top small cap pick heading into 2016 saying revenue acceleration could lead to multiple expansion. The analyst notes his thesis centers around the durability of the company's invasive breast cancer testing franchise, rather than uptake of its prostate cancer test. He keeps an Outperform rating on Genomic with a $38 price target.
News For GHDX From the Last 2 Days
There are no results for your query GHDX
